IBIOiBio, Inc.
Sign up free
Thesis

First-in-class Activin E antibody with fat-selective preclinical profile bets on human translation before IND is filed

Updated 18d ago

iBio is an early-stage biopharmaceutical company developing a candidate treatment for obesity and Type 2 diabetes that is not yet approved and has not yet entered human testing.

IBIO-610, a first-in-class Activin E antibody targeting obesity and Type 2 diabetes, has not yet entered human testing; the entire bull case rests on whether fat-selective weight loss and GLP-1 synergy seen in rodents and non-human primates translate to humans. IBIO-600, a cardiometabolic antibody, completed Phase 1 SAD dosing without safety flags, providing the only human clinical data in the portfolio. The $88M cash position funds operations into fiscal 2028, but the company must raise again well before any IBIO-610 efficacy readout emerges.

Status
Intact
Conviction

Current Thesis Drivers

  • NHP single dose: 98% Activin E suppression at week 4
  • IBIO-600 SAD: 31/32 dosed, no dose-limiting safety findings
  • $88M cash; runway into fiscal 2028 per company guidance
  • IBIO-610 IND not yet filed; zero human efficacy data

What could change the thesis?

  • IBIO-610 IND clearance: enables Phase 1, delay or hold breaks near-term timeline
  • IBIO-600 MAD readout: safety signal halts program, clean data de-risks platform
  • IBIO-610 Phase 1 first-in-human data: human translation confirmed or preclinical story collapses

Generated from public SEC filings and disclosures. For informational purposes only — not investment advice. Always conduct your own research before making investment decisions.

Thesis log

Tracked in real time as it happened — not reconstructed after the fact

Key value driver

The most decisive event ahead

Bull and bear case

Both sides of the thesis, argued

Pipeline

6 programs · 9 catalysts

Stress Test